Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 11469-11477

  Lu, Huaiwu ^a   Liu, Yunyun ^a   Wang, Dongyan ^a   Wang, Lijuan ^a   Zhou, Hui ^a   Xu, Guocai ^a   Xie, Lingling ^a   Wu, Miaofang ^a   Lin, Zhongqiu ^a   Yu, Yuefei ^b   Li, Guorong ^c,d  

^a SUN YAT SEN UNIVERSITY   (China)

^b Novatek Pharmaceuticals   (United States)

^c Sainbiose   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Carboplatin chemoresistance; Epithelial ovarian cancer; Galectin 3; NF B; Pathway

Indexed keywords

CARBOPLATIN; GALECTIN 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; GALECTIN-3, HUMAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; METASTASIS POTENTIAL; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CONFOCAL MICROSCOPY; DRUG RESISTANCE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GALECTIN 3; HUMANS; MICROSCOPY, CONFOCAL; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NF-KAPPA B; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84961589584     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5004-3     Document Type: Article

References (35)

1. Kigawa J. New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med. 2013;56:43–50.
2. Stewart LA, Guthrie D, Parmar MK, Williams CJ. Chemotherapy in advanced ovarian cancer. BMJ. 1992;304:119.
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
5. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272–6.
6. Hoyer KK, Pang M, Gui D, Shintaku IP, Kuwabara I, Liu FT, et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol. 2004;164:893–902.
7. Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002;9:1307–12.
8. Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, et al. Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate. 2008;68:72–7.
9. Brustmann H. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol. 2008;27:380–9.
10. Oishi T, Itamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M, et al. Galectin-3 may contribute to cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2007;17:1040–6.
11. Kim MK, Sung CO, Do IG, Jeon HK, Song TJ, Park HS, et al. Overexpression of galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol. 2011;16:352–8.
12. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785–99.
13. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000;60:5334–9.
14. Andela VB, Schwarz EM, Puzas JE, O’Keefe RJ, Rosier RN. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res. 2000;60:6557–62.
15. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241–6.
16. Kadrofske MM, Openo KP, Wang JL. The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys. 1998;349:7–20.
17. Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, et al. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 2014;135:573–9.
18. Nangia-Makker P, Balan V, Raz A. Galectin-3 binding and metastasis. Methods Mol Biol. 2012;878:251–66.
19. Wu KL, Huang EY, Jhu EW, Huang YH, Su WH, Chuang PC, et al. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol. 2013;48:350–9.
20. Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, Tsutsumi S, et al. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer. 2011;129:2775–86.
21. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, Park SH, et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology. 2010;138:1035–45.e1-2.
22. Covens A, Carey M, Bryson P, Verma S, Fung KFM, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol. 2002;85:71–80.
23. Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res. 2002;107:99–118.
24. Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM, Moore Jr FD, et al. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun. 2009;379:626–31.
25. Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis. 2010;1:e101.
26. Wongkham S, Junking M, Wongkham C, Sripa B, Chur-In S, Araki N. Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma. Cancer Sci. 2009;100:2077–84.
27. Hossein G, Keshavarz M, Ahmadi S, Naderi N. Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 2013;14:7561–8.
28. Choi YK, Cho SG, Woo SM, Yun YJ, Jo J, Kim W, et al. Saussurea lappa Clarke-derived costunolide prevents TNF alpha-induced breast cancer cell migration and invasion by inhibiting NF-kappa B activity. Evid Based Complement Alternat Med. 2013;2013:936257.
29. Lu KW, Chen JC, Lai TY, Yang JS, Weng SW, Ma YS, et al. Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2 -9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways. Hum Exp Toxicol. 2011;30:406–15.
30. Zeng W, Chang H, Ma M, Li Y. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol. 2014;97:184–90.
31. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem. 2004;279:23477–85.
32. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem. 1997;272:14914–20.
33. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res. 2004;10:7645–54.
34. Dumic J, Lauc G, Flogel M. Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell Physiol Biochem. 2000;10:149–58.
35. Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, et al. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer. Int Rev Immunol. 2014;33:417–27.